1528 - Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast

Page last updated: 18 March 2020

Application Detail



Description of Medical Service

Characterisation of VHL, TP53, RB1 status, TFE3 / Xp11.1 translocation and detection of chromosome 3 (chr3) monosomy for the diagnosis of RCC; characterisation of ploidy status for the diagnosis and classification of patients with hydatidiform moles; classification of mutation in FOXL2 (402C>G) for the diagnosis of granulosa cell ovarian tumour; detection of somatic gene rearrangements for the diagnosis of salivary gland tumours including mammary analogue secretory carcinoma, hyalinising clear cell carcinoma, mucoepidermoid and NUT midline carcinomas; and characterisation of somatic tumour gene rearrangements for the diagnosis of secretory carcinoma of the breast.

Description of Medical Condition

Renal cell carcinoma (RCC); hydatidiform moles; granulosa cell ovarian tumour; salivary gland tumours; and secretory carcinoma of the breast.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (Word 191 KB)
Application Form (PDF 1060 KB)

Consultation Survey

Consultation Survey (Word 508 KB)
Consultation Survey (PDF 304 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (Word 81 KB)
Public Summary Document (PDF 377 KB)

Meetings for this Application


12-13 April 2018




1-2 August 2019
28-29 November 2019